Cancer vaccine trial seeks to boost Body's defenses against tumors
NCT ID NCT06011772
Summary
This early-phase study is testing whether adding an experimental vaccine called CIMAvax-EGF to standard colorectal cancer treatments can help the patient's immune system fight the cancer. It will enroll a small number of people with advanced colorectal cancer that has spread and has specific genetic markers. The main goal is to see if the vaccine successfully triggers an immune response against the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLO-RECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Roswell Park Comprehensive Cancer Center
Buffalo, New York, 14263, United States
Conditions
Explore the condition pages connected to this study.